The Week in Review: Henan Taloph Pharma Raises $63 Million, Phytoceutica, Inc. Plans to Move its TCM-based Lead Drug into US Clinical Trials
Published: Apr 09, 2012
April 7, 2012 -- Henan Taloph Pharma will raise $63.4 million in a private placement to fund several capex projects; PhytoCeutica of Connecticut plans to move its TCM-based lead drug into US clinical trials as an adjuvant to chemotherapy; Zhejiang Hisun Pharma has successfully filed an IND application with the FDA for an innovative statin; Agenix plans to file an application in Q3 with the SFDA to begin China clinical trials of a hepatitis B treatment; and Barclays issued a new outlook for the stocks of China healthcare companies, based in part on a ChinaBio® survey. More details....
Stock Symbol: (SHA: 600222) (SHA: 600267) (ASX: AGX)